BMS-777607: Selective c-Met Inhibitor for Cancer Metastasis Research

Principle and Scientific Rationale: Harnessing BMS-777607 in Cancer Research

BMS-777607, supplied by APExBIO, is an orally available, ATP-competitive MET kinase inhibitor designed to provide precise inhibition of the MET kinase family—including c-Met, Axl, Ron, and Tyro3. Its nanomolar potency (IC₅₀ values: 3.9 nM for c-Met, 1.1 nM for Axl, 1.8 nM for Ron, and 4.3 nM for Tyro3) and 40- to 500-fold selectivity over unrelated kinases (e.g., Lck, VEGFR-2, and TrkA/B) enable researchers to interrogate MET signaling pathway inhibition with minimal off-target effects. Mechanistically, BMS-777607 blocks auto-phosphorylation of c-Met, disrupting downstream tyrosine kinase signaling critical for tumor growth, metastasis, and cell survival.

This small molecule kinase inhibitor is especially relevant for cancer metastasis research, apoptosis and metastasis suppression, and advanced preclinical models. Its proven efficacy in both in vitro and in vivo settings—including significant reduction of lung tumor nodules in KHT xenograft mice—positions BMS-777607 as a cornerstone compound for investigating c-Met driven tumor growth inhibition and RTK signaling inhibition in prostate and breast cancer models.

Optimized Experimental Workflows: From Stock Preparation to In Vivo Models

1. Compound Preparation and Handling

• Solubility: BMS-777607 is soluble in DMSO (≥25.65 mg/mL). For optimal dissolution, warm the solution to 37°C and apply ultrasonic shaking. It is insoluble in water and ethanol.
• Storage: Dried compound is stable at -20°C. Once dissolved, store stock solutions at -20°C for short-term use and avoid long-term storage to preserve potency.
• Shipping: The product is shipped on blue ice to ensure molecular integrity.

2. In Vitro Workflow: MET Signaling Pathway Inhibition

• Cell Line Selection: Choose models dependent on c-Met, Axl, Ron, or Tyro3 signaling (e.g., murine KHT, human prostate/breast cancer lines).
• Inhibitor Treatment: Apply BMS-777607 at concentrations ranging from 1–10 μM. In KHT cells, 10 μM abolishes basal c-Met autophosphorylation.
• Readouts: Analyze phosphorylation status via Western blot or ELISA, assess cell viability (MTT/XTT), and quantify apoptosis/metastatic markers (e.g., flow cytometry for Annexin V/PI, invasion assays).
• Polyploidy Induction: For breast cancer or megakaryocyte differentiation studies, apply BMS-777607 during the polyploidization phase to enhance nuclear content, as demonstrated in optimized in vitro differentiation protocols (reference study).

3. In Vivo Workflow: Tumor Xenograft Growth Inhibition

• Model Establishment: Inject target cancer cells (e.g., KHT, prostate, or breast cancer) into immunodeficient mice.
• Dosing: Administer BMS-777607 orally at 25 mg/kg/day. In KHT xenograft models, this regimen reduced lung tumor nodules by 28.3% and improved tumor morphology without systemic toxicity.
• Endpoints: Assess tumor burden (volume, weight), metastatic spread (histology), and animal health (weight, serum chemistry).

Advanced Applications and Comparative Advantages

Selective Tyrosine Kinase Inhibition in Cancer Biology

BMS-777607 is distinguished as a selective c-Met kinase inhibitor for cancer research, offering robust performance in:

• Cancer Metastasis Models: Suppressing MET-driven invasiveness and metastatic phenotype in prostate and breast cancer.
• Apoptosis and Metastasis Suppression: Triggering apoptosis and impeding metastatic signaling by blocking c-Met, Ron, and Axl phosphorylation.
• Polyploidy Induction: Enhancing megakaryocyte (MK) polyploidization and breast cancer cell polyploidy for studies of cell differentiation and thrombopoiesis, as highlighted in the reference study. This approach shortens differentiation time and boosts platelet yield in iPSC-derived MK cultures by optimizing small-molecule supplementation.

Comparative Insights: Literature-Driven Best Practices

Several expert articles extend or complement the practical application of BMS-777607:

• "BMS-777607: Selective c-Met Inhibitor for Advanced Cancer Research" explores how this inhibitor enables precise control over tyrosine kinase signaling and can be leveraged to troubleshoot cell differentiation workflows—an extension of the reference study's focus on polyploidy and differentiation efficiency.
• "BMS-777607 (SKU A5703): Practical Solutions for MET Kinase Inhibition Assays" provides scenario-based troubleshooting guidance, complementing the current protocol by addressing common pitfalls in kinase inhibition experiments and enhancing reproducibility in cancer metastasis research.
• "BMS-777607: Selective c-Met Inhibitor for Cancer and Metastasis Models" summarizes preclinical data on efficacy and selectivity, reinforcing the advantages observed in both in vitro and in vivo settings.

Together, these resources provide a framework for integrating BMS-777607 into multifaceted cancer biology and differentiation models, optimizing both discovery and translational research pipelines.

Troubleshooting and Optimization: Ensuring Success with BMS-777607

Common Challenges and Solutions

• Solubility Issues: If BMS-777607 fails to dissolve completely in DMSO, pre-warm the solvent to 37°C and use ultrasonic agitation. Avoid water and ethanol as solvents due to insolubility.
• Stock Solution Degradation: To maintain inhibitor potency, prepare fresh aliquots as needed and store at -20°C. Minimize freeze-thaw cycles and use within days of dissolution.
• Off-Target Effects: While BMS-777607 is highly selective, concentrations above 10 μM may inhibit kinases such as VEGFR2 and Lck. For specificity, titrate doses in pilot assays and monitor off-target signaling via phospho-protein arrays.
• Cellular Toxicity: Use viability assays (e.g., MTT, trypan blue exclusion) to distinguish between on-target cytostatic/cytotoxic effects and non-specific toxicity.
• Batch-to-Batch Consistency: Source BMS-777607 from reputable suppliers such as APExBIO to ensure reproducibility. Validate each lot by confirming IC₅₀ values in a control assay.

Protocol Enhancements for Specialized Applications

• Combination Strategies: For iPSC-derived platelet protocols, combine BMS-777607 with other small molecules (e.g., 740Y-P, butyzamide, blebbistatin, 616452) to synergistically enhance megakaryocyte polyploidization and platelet output, as established in the reference study. This multi-pronged approach reduced cost by 58.3% and increased yield to 14.9 platelets per iPSC.
• Metastasis Models: In xenograft studies, pair BMS-777607 with imaging modalities (bioluminescence, MRI) for real-time monitoring of tumor regression and metastatic suppression.
• Signaling Pathway Dissection: Use phosphoproteomics or multiplexed ELISA to monitor broad RTK signaling inhibition and confirm specificity for c-Met, Ron, Axl, and Tyro3.

Future Outlook: Unlocking New Frontiers with BMS-777607

As cancer biology and regenerative medicine converge, the versatility of BMS-777607 as a selective tyrosine kinase inhibitor promises to drive innovation across fields. Its dual utility in suppressing tumor metastasis and enabling high-efficiency differentiation (e.g., polyploidy induction in MKs and cancer cells) opens pathways for:

• Personalized Oncology: Integration into patient-derived xenograft (PDX) models to evaluate individualized metastatic phenotypes and therapy response.
• Cell Therapy Manufacturing: Streamlining the scalable production of functional platelets from iPSCs, reducing reliance on donor-derived products and addressing global shortages.
• Mechanistic Discovery: Dissecting the c-Met signaling pathway and its role in apoptosis, proliferation, and chemoresistance, facilitating the design of next-generation combination therapies.

Researchers are encouraged to leverage the proven selectivity and reproducibility of BMS-777607 for cancer research, drawing on validated protocols, comparative literature, and the trusted supply chain of APExBIO. As demonstrated through both reference studies and application-driven articles, this ATP-competitive MET kinase inhibitor continues to empower breakthroughs in tumor metastasis inhibition, selective RTK signaling blockade, and the optimization of preclinical research models.